Literature DB >> 9751730

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.

B Olofsson1, E Korpelainen, M S Pepper, S J Mandriota, K Aase, V Kumar, Y Gunji, M M Jeltsch, M Shibuya, K Alitalo, U Eriksson.   

Abstract

The vascular endothelial growth factor (VEGF) family has recently expanded by the identification and cloning of three additional members, namely VEGF-B, VEGF-C, and VEGF-D. In this study we demonstrate that VEGF-B binds selectively to VEGF receptor-1/Flt-1. This binding can be blocked by excess VEGF, indicating that the interaction sites on the receptor are at least partially overlapping. Mutating the putative VEGF receptor-1/Flt-1 binding determinants Asp63, Asp64, and Glu67 to alanine residues in VEGF-B reduced the affinity to VEGF receptor-1 but did not abolish binding. Mutational analysis of conserved cysteines contributing to VEGF-B dimer formation suggest a structural conservation with VEGF and platelet-derived growth factor. Proteolytic processing of the 60-kDa VEGF-B186 dimer results in a 34-kDa dimer containing the receptor-binding epitopes. The binding of VEGF-B to its receptor on endothelial cells leads to increased expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1, suggesting a role for VEGF-B in the regulation of extracellular matrix degradation, cell adhesion, and migration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751730      PMCID: PMC21705          DOI: 10.1073/pnas.95.20.11709

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Production of single-stranded plasmid DNA.

Authors:  J Vieira; J Messing
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

2.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).

Authors:  M G Achen; M Jeltsch; E Kukk; T Mäkinen; A Vitali; A F Wilks; K Alitalo; S A Stacker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

3.  Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations.

Authors:  A J Pötgens; N H Lubsen; M C van Altena; R Vermeulen; A Bakker; J G Schoenmakers; D J Ruiter; R M de Waal
Journal:  J Biol Chem       Date:  1994-12-30       Impact factor: 5.157

4.  Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5' flanking region.

Authors:  R Fisher; E K Waller; G Grossi; D Thompson; R Tizard; W D Schleuning
Journal:  J Biol Chem       Date:  1985-09-15       Impact factor: 5.157

5.  In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis.

Authors:  E Bacharach; A Itin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

6.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.

Authors:  J E Park; H H Chen; J Winer; K A Houck; N Ferrara
Journal:  J Biol Chem       Date:  1994-10-14       Impact factor: 5.157

7.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.

Authors:  L Seetharam; N Gotoh; Y Maru; G Neufeld; S Yamaguchi; M Shibuya
Journal:  Oncogene       Date:  1995-01-05       Impact factor: 9.867

8.  Cultured endothelial cell monolayers that restrict the transendothelial passage of macromolecules and electrical current.

Authors:  M B Furie; E B Cramer; B L Naprstek; S C Silverstein
Journal:  J Cell Biol       Date:  1984-03       Impact factor: 10.539

9.  Upregulation of urokinase receptor expression on migrating endothelial cells.

Authors:  M S Pepper; A P Sappino; R Stöcklin; R Montesano; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

10.  Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages.

Authors:  J D Vassalli; J M Dayer; A Wohlwend; D Belin
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

View more
  119 in total

Review 1.  Effect of inflammatory cytokines on the expression of the vascular endothelial growth factor-C.

Authors:  K Narko; B Enholm; T Mäkinen; A Ristimäki
Journal:  Int J Exp Pathol       Date:  1999-06       Impact factor: 1.925

Review 2.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

3.  VEGF-B: a thing of beauty.

Authors:  Xuri Li
Journal:  Cell Res       Date:  2010-06-08       Impact factor: 25.617

Review 4.  Cellular and molecular mechanisms of embryonic haemangiogenesis and lymphangiogenesis.

Authors:  Jörg Wilting; Bodo Christ; Li Yuan; Anne Eichmann
Journal:  Naturwissenschaften       Date:  2003-09-17

5.  Double target for tumor mass destruction.

Authors:  Pipsa Saharinen; Kari Alitalo
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 6.  New molecular targets for treatment of lymphoma.

Authors:  Barbara Pro; Anas Younes
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 7.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 8.  Overcoming resistance to antiangiogenic therapies.

Authors:  Sabine Tejpar; Hans Prenen; Massimiliano Mazzone
Journal:  Oncologist       Date:  2012-07-06

Review 9.  Endothelial fatty acid transport: role of vascular endothelial growth factor B.

Authors:  Carolina Hagberg; Annika Mehlem; Annelie Falkevall; Lars Muhl; Ulf Eriksson
Journal:  Physiology (Bethesda)       Date:  2013-03

10.  Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.

Authors:  Kilian Guse; Marta Sloniecka; Iulia Diaconu; Kathryn Ottolino-Perry; Nan Tang; Calvin Ng; Fabrice Le Boeuf; John C Bell; J Andrea McCart; Ari Ristimäki; Sari Pesonen; Vincenzo Cerullo; Akseli Hemminki
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.